NCT02744365 Biobank on Prematurity, Preeclampsia and Other Pregnancy Complications
| NCT ID | NCT02744365 |
| Status | Recruiting |
| Phase | — |
| Sponsor | CHU de Quebec-Universite Laval |
| Condition | Preeclampsia |
| Study Type | OBSERVATIONAL |
| Enrollment | 7,845 participants |
| Start Date | 2015-04 |
| Primary Completion | 2025-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 7,845 participants in total. It began in 2015-04 with a primary completion date of 2025-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Biobank includes data and biological specimens of women from three original studies: 1) First-trimester Prediction of Preeclampsia (PREDICTION Study, NCT02189148), 2) Pre-Eclampsia And growth Retardation, an evaluative Longitudinal study (PEARL Study, NCT02379832), 3) Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial (NCT02280031) and 4)PREDICTION2: Prediction of Preeclampsia and other Pregnancy Complications Following Combined Iterative Screening.
Eligibility Criteria
Inclusion Criteria: * (specific to each study) Exclusion Criteria: * pregnant women \<18 years old at recruitment * negative fetal heart at recruitment * women not able to provide an informed consent to the study
Contact & Investigator
Emmanuel Bujold, MD, MSc
PRINCIPAL INVESTIGATOR
CHU de Quebec
Frequently Asked Questions
Who can join the NCT02744365 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Preeclampsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02744365 currently recruiting?
Yes, NCT02744365 is actively recruiting participants. Contact the research team at emmanuel.bujold@crchudequebec.ulaval.ca for enrollment information.
Where is the NCT02744365 trial being conducted?
This trial is being conducted at Québec, Canada.
Who is sponsoring the NCT02744365 clinical trial?
NCT02744365 is sponsored by CHU de Quebec-Universite Laval. The principal investigator is Emmanuel Bujold, MD, MSc at CHU de Quebec. The trial plans to enroll 7,845 participants.